Skip to content
OpenCapital
Get started

Edgewise Therapeutics, Inc. EWTX Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Cytokinetics logo
CytokineticsCYTK
4.2×-1.8×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
6.8×+0.9×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
19.9×-0.4×
Viking Therapeutics logo
Viking TherapeuticsVKTX
5.7×-38.5×

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0×0.0×
Current ratio22.6×+1.6×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

quick assets/total current liabilities=22.6×

Based on the most recent quarter.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s quick ratio?
Edgewise Therapeutics, Inc. (EWTX) reported quick ratio of 22.6× in Q1 2026.
How has Edgewise Therapeutics, Inc.'s quick ratio changed year-over-year?
Edgewise Therapeutics, Inc.'s quick ratio increased by 7.7% year-over-year, from 21× to 22.6×.
What is the long-term trend for Edgewise Therapeutics, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s quick ratio has grown at a -7.8% compound annual growth rate (CAGR), from 29.9× to 19.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.